Chronic HBV infection is a global public health burden estimated to impact nearly 300
million persons worldwide. Despite the advent of potent antiviral agents that effectively …

During hepatitis B virus (HBV) infection, the presence of HBV-specific antibody producing B
cells and functional HBV-specific T cells (with helper or cytotoxic effects) ultimately …

Chronic hepatitis B virus (HBV) infection is one of the high-risk factors for human HCC.
Despite the integration of virus DNA and the oncoprotein HBx, chronic necroinflammation …

Chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infections account for 57% of
cases of liver cirrhosis and 78% of cases of primary liver cancer worldwide and cause a …

The liver is a unique anatomical and immunological site in which antigen‐rich blood from
the gastrointestinal tract is pressed through a network of sinusoids and scanned by antigen …

Fas ligand (FasL), a cell surface molecule belonging to the tumor necrosis factor family,
binds to its receptor Fas, thus inducing apoptosis of Fas-bearing cells. Various cells express …

More than 500 million people worldwide are persistently infected with the hepatitis B virus
(HBV) and/or hepatitis C virus (HCV) and are at risk of developing chronic liver disease …

Infection with hepatitis B virus (HBV) results in disparate degrees of tissue injury: the virus
can either replicate without pathological consequences or trigger immune-mediated …

Hepatitis B virus (HBV) is a noncytopathic virus, and the recognition of infected hepatocytes
by HBV-specific CD8 cells has been assumed to be the central mechanism causing both …

Among the many viruses that are known to infect the human liver, hepatitis B virus (HBV)
and hepatitis C virus (HCV) are unique because of their prodigious capacity to cause …